UGT1A1 polymorphisms in cancer: impact on irinotecan treatment

References

• StintzingSModestDPRossiusLFOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trialLancet Oncol201617101426143427575024
   PubMed Web of Science ®Google Scholar
• NodaKNishiwakiYKawaharaMIrinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancerN Engl J Med20023462859111784874
   PubMed Web of Science ®Google Scholar
• BokuNYamamotoSFukudaHFluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 studyLancet Oncol200910111063106919818685
   PubMed Web of Science ®Google Scholar
• SugiyamaTOkamotoAEnomotoTRandomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017/GCIG trialJ Clin Oncol201634242881288727400948
   PubMed Web of Science ®Google Scholar
• SugiyamaTNishidaTKumagaiSCombination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancerBr J Cancer1999811959810487618
   PubMed Web of Science ®Google Scholar
• IyerLKingCDWhitingtonPFGenetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomesJ Clin Invest199810148478549466980
   PubMed Web of Science ®Google Scholar
• InnocentiFKroetzDLSchuetzEComprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokineticsJ Clin Oncol200927162604261419349540
   PubMed Web of Science ®Google Scholar
• MeraliZRossSParéGThe pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effectDrug Metabol Drug Interact201429314315124988246
   PubMedGoogle Scholar
• De MattiaEToffoliGPoleselJPharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatmentPharmacogenet Genomics2013231054955724018773
   PubMed Web of Science ®Google Scholar
• BosmaPJChowdhuryJRBakkerCThe genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndromeN Engl J Med199533318117111757565971
   PubMed Web of Science ®Google Scholar
• BosmaPJChowdhuryNRGoldhoornBGSequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type IHepatology19921559419471568736
   PubMed Web of Science ®Google Scholar
• KadakolAGhoshSSSappalBSSharmaGChowdhuryJRChowdhuryNRGenetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotypeHum Mutat200016429730611013440
   PubMed Web of Science ®Google Scholar
• PharmacogenomicsKnowledge. Implementation (PharmGKB) [web-page on the Internet]. Haplotypes for UGT1A1 (UGT Alleles Nomenclature Page) Available from: https://www.pharmgkb.org/haplotypeSet/ PA166115840Accessed January 12, 2017
   Google Scholar
• OMIM [webpage on the Internet]UDP-Glycosyltransferase 1 Family, Polypeptide A1UGT1A1 Available from: http://omim.org/entry/191740Accessed January 12, 2017
   Google Scholar
• BeutlerEGelbartTDeminaARacial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?Proc Natl Acad Sci U S A19989514817081749653159
   PubMed Web of Science ®Google Scholar
• KaniwaNKuroseKJinnoHRacial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-AmericanDrug Metab Dispos200533345846515572581
   PubMed Web of Science ®Google Scholar
• MaruoYNakaharaSYanagiTGenotype of UGT1A1 and phenotype correlation between Crigler-Najjar syndrome type II and Gilbert syndromeJ Gastroenterol Hepatol201631240340826250421
   PubMed Web of Science ®Google Scholar
• LeeJSWangJMartinMGenetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumabPharmacogenet Genomics201121736537421412181
   PubMed Web of Science ®Google Scholar
• UdomuksornWElliotDJLewisBCMackenziePIYoovathawornKMinersJOInfluence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substratesPharmacogenet Genomics200717121017102918004206
   PubMed Web of Science ®Google Scholar
• BosmaPJvan der MeerIMBakkerCTUGT1A1*28 allele and coronary heart disease: the Rotterdam StudyClin Chem20034971180118112816916
   PubMed Web of Science ®Google Scholar
• LinJPO’DonnellCJSchwaigerJPAssociation between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart StudyCirculation2006114141476148117000907
   PubMed Web of Science ®Google Scholar
• ToffoliGCecchinECoronaGThe role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancerJ Clin Oncol200624193061306816809730
   PubMed Web of Science ®Google Scholar
• DiasMMMcKinnonRASorichMJImpact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysisPharmacogenomics201213888989922676194
   PubMed Web of Science ®Google Scholar
• DiasMMPignonJPKarapetisCSThe effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysisPharmacogenomics J201414542443124709690
   PubMed Web of Science ®Google Scholar
• LiuXChengDKuangQLiuGXuWAssociation between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in CaucasiansPLoS One201383e5848923516488
   PubMed Web of Science ®Google Scholar
• RouitsEBoisdron-CelleMDumontAGuérinOMorelAGamelinERelevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patientsClin Cancer Res200410155151515915297419
   PubMed Web of Science ®Google Scholar
• MarcuelloEAltésAMenoyoADel RioEGómez-PardoMBaigetMUGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancerBr J Cancer200491467868215280927
   PubMed Web of Science ®Google Scholar
• CôtéJFKirzinSKramarAUGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecanClin Cancer Res200713113269327517510208
   PubMed Web of Science ®Google Scholar
• KweekelDMGelderblomHVan der StraatenTUGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group studyBr J Cancer200899227528218594531
   PubMed Web of Science ®Google Scholar
• BraunMSRichmanSDThompsonLAssociation of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trialJ Clin Oncol200927335519552819858398
   PubMed Web of Science ®Google Scholar
• FerraldeschiRMinchellLJRobertsSAUGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecanPharmacogenomics200910573373919450125
   PubMed Web of Science ®Google Scholar
• McLeodHLSargentDJMarshSPharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741J Clin Oncol201028203227323320530282
   PubMed Web of Science ®Google Scholar
• Martinez-BalibreaEAbadAMartínez-CardúsAUGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapyBr J Cancer2010103458158920628391
   PubMed Web of Science ®Google Scholar
• GlimeliusBGarmoHBerglundAPrediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancerPharmacogenomics J2011111617120177420
   PubMed Web of Science ®Google Scholar
• ShulmanKCohenIBarnett-GrinessOClinical implications of UGT1A1*28 genotype testing in colorectal cancer patientsCancer2011117143156316221287524
   PubMed Web of Science ®Google Scholar
• LamasMJDuranGBalboaEThe value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimensCancer Chemother Pharmacol20126961591159922535333
   PubMed Web of Science ®Google Scholar
• HoskinsJMGoldbergRMQuPIbrahimJGMcLeodHLUGT1A1*28 genotype and irinotecan-induced neutropenia: dose mattersJ Natl Cancer Inst200799171290129517728214
   PubMedGoogle Scholar
• HuZYYuQPeiQGuoCDose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase riskClin Cancer Res201016153832384220562211
   PubMed Web of Science ®Google Scholar
• LiuXChengDKuangQLiuGXuWAssociation of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in CaucasiansPharmacogenomics J201414212012923529007
   PubMed Web of Science ®Google Scholar
• JadaSRLimRWongCIRole of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patientsCancer Sci20079891461146717627617
   PubMed Web of Science ®Google Scholar
• SaiKSaitoYSakamotoHImportance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patientsCancer Lett2008261216517118082937
   PubMed Web of Science ®Google Scholar
• TakanoMKatoMYoshikawaTClinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional studyOncology200976531532119299905
   PubMed Web of Science ®Google Scholar
• SeoBGKwonHCOhSYComprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRIOncol Rep200922112713619513514
   PubMed Web of Science ®Google Scholar
• OnoueMTeradaTKobayashiMUGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patientsInt J Clin Oncol200914213614219390945
   PubMed Web of Science ®Google Scholar
• SatohTUraTYamadaYGenotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphismsCancer Sci2011102101868187321740478
   PubMed Web of Science ®Google Scholar
• OkuyamaYHazamaSNozawaHProspective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphismsJpn J Clin Oncol201141447748221303789
   PubMed Web of Science ®Google Scholar
• WangYShenLXuNUGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracilWorld J Gastroenterol201218456635664423236239
   PubMed Web of Science ®Google Scholar
• GaoJZhouJLiYLuMJiaRShenLUGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patientsMed Oncol201330360423686699
   PubMed Web of Science ®Google Scholar
• GaoJZhouJLiYAssociations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patientsMed Oncol201330363023783485
   PubMed Web of Science ®Google Scholar
• IchikawaWUeharaKMinamimuraKAn internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patientsBr J Cancer2015112101709171625880011
   PubMed Web of Science ®Google Scholar
• ChengLLiMHuJUGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in AsiansCancer Chemother Pharmacol201473355156024448639
   PubMed Web of Science ®Google Scholar
• ToffoliGCecchinEGaspariniGGenotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancerJ Clin Oncol201028586687120038727
   PubMed Web of Science ®Google Scholar
• MarcuelloEPáezDParéLA genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancerBr J Cancer20111051535721654688
   PubMed Web of Science ®Google Scholar
• KimKPHongYSLeeJLA phase I study of UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRIOncology201588316417225427841
   PubMed Web of Science ®Google Scholar
• HazamaSNagashimaAKondoHPhase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphismCancer Sci2010101372272720028383
   PubMed Web of Science ®Google Scholar
• LuCYHuangCWHuHMPrognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line settingTransl Res2014164216917624462762
   PubMed Web of Science ®Google Scholar
• Camptosar [prescribing information] [webpage on the Internet] Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=533Accessed January 12, 2017
   Google Scholar
• SchmollHJVan CutsemESteinAESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision makingAnn Oncol201223102479251623012255
   PubMed Web of Science ®Google Scholar
• WatanabeTItabashiMShimadaYJapanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancerInt J Clin Oncol201520220723925782566
   PubMed Web of Science ®Google Scholar